# Neurocrine Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurocrine-biosciences

- Industry: Healthcare
- Headquarters: San Diego, US
- Website: www.neurocrine.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Jun 1, 1992)
- Investors on record: 4

## About

Founded in 1992, Neurocrine Biosciences, Inc. focuses on discovering and developing innovative treatments for neurological, neuroendocrine, and neuropsychiatric disorders, providing critical therapeutic options for patients in need. Neurocrine Biosciences specializes in creating treatments for neurological disorders and was founded in San Diego, US. In May 2026, Neurocrine Biosciences raised USD 600 million debt funding from JPMorgan Chase. The CEO of the company is Kevin Gorman. Neurocrine Biosciences, Inc. specializes in the discovery and development of innovative treatments for patients with neurological, neuroendocrine, and neuropsychiatric disorders. The company’s core product offerings include therapeutics aimed at addressing conditions such as movement disorders and endocrine-related diseases. These treatments are designed to alleviate suffering for patients who currently lack viable therapeutic options, thus fulfilling a critical need in the healthcare landscape. Neurocrine's solutions serve a diverse clientele that includes healthcare providers, hospitals, and specialty pharmacies, directly impacting end users who seek relief from debilitating conditions. The company is actively engaged in various markets, primarily focusing on regions such as North America and Europe, where the demand for advanced medical treatments in these therapeutic areas is significant.Neurocrine Biosciences generates revenue through the commercialization of its pharmaceutical products, which are sold primarily through direct-to-consumer channels and partnerships with healthcare providers. The revenue for the most recent year 2024 amounts to USD 2.33 bn, with an EBITDA of USD 597.60 mn. The transaction structure typically involves agreements with hospitals and pharmacies that facilitate the distribution of their therapeutics. Revenue is derived from the sale of flagship products that cater to specific disorders such as tardive dyskinesia. The pricing of these products reflects the specialized nature of the treatments and the research invested in their development. The company’s revenue model is bolstered by ongoing collaborations and potential licensing agreements that enhance its market reach and therapeutic offerings, reinforcing its commitment to addressing significant health needs in the communities it serves. The company plans to utilize the May 2026 funding to improve its cash flow and adaptability for key projects and potential purchases.

## Funding rounds

- Series A, Jun 1, 1992, $3.5M — Kleiner Perkins, Avalon Ventures, Schroder Ventures, David Blech & Company Incorporated

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series A
- Schroder Ventures (https://capitalatlas.ai/funds/schroder-ventures) — Series A
- David Blech & Company Incorporated — Series A